by Suman L. Sood, Dunlei Cheng, Margaret Ragni, Craig M

Slides:

Advertisements

Similar presentations

by Johnny Mahlangu, Jerry S. Powell, Margaret V

Advertisements

Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival by Sandra L. Haberichter,

Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.

Total arterial revascularization of triple vessel coronary disease based on combined internal thoracic and radial artery grafts Robert H. Habib, PhD,

by Nadine Martel, James Lee, and Philip S. Wells

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

by Annette von Drygalski, and John W. Adamson

The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting Danny Chu, MD, Faisal.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Coronary revascularisation rate (total 5

Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial Edward.

(p for noninferiority < 0.001)

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Surgical economics: MACRA, MIPS, and bundles—Lessons learned in the first 3 years of a coronary artery bypass grafting alternative payment model Daniel.

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Predictors of long-term patient survival after in situ vein leg bypass

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease Neuza Helena Lopes, MD, PhD, Felipe da Silva Paulitsch, MD,

Volume 2(Supplement 1):1-3

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

by Christine L. Kempton, and Amanda B. Payne

Characteristics of included studies

Volume 2(Supplement 1):46-49

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Timothy J. Gardner, M. D. , Peter J. Horneffer, M. D. , Teri A

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

MATRIX: Radial vs. Femoral

Glenn N. Levine et al. JACC 2011;58:e44-e122

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Volume 2(Supplement 1):39-41

Baseline characteristics of study population

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking by Juliet N. Barker, Jane Kempenich, Joanne.

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis by Juliet N. Barker, Kirsten Boughan, Parastoo.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Volume 2(Supplement 1):4-7

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

A cross-sectional analysis of cardiovascular disease in the hemophilia population by Suman L. Sood, Dunlei Cheng, Margaret Ragni, Craig M. Kessler, Doris Quon, Amy D. Shapiro, Nigel S. Key, Marilyn J. Manco-Johnson, Adam Cuker, Christine Kempton, Tzu-Fei Wang, M. Elaine Eyster, Philip Kuriakose, Annette von Drygalski, Joan Cox Gill, Allison Wheeler, Peter Kouides, Miguel A. Escobar, Cindy Leissinger, Sarah Galdzicka, Marshall Corson, Crystal Watson, and Barbara A. Konkle BloodAdv Volume 2(11):1325-1333 June 12, 2018 © 2018 by The American Society of Hematology

Suman L. Sood et al. Blood Adv 2018;2:1325-1333 © 2018 by The American Society of Hematology

The distribution of CVD events and procedures among 30 subjects with CVD. The number of subjects who experienced CVD events (angina, MI, TIA, or stroke) alone or in combination with other events or procedures (coronary artery bypass grafting or angioplasty). The distribution of CVD events and procedures among 30 subjects with CVD. The number of subjects who experienced CVD events (angina, MI, TIA, or stroke) alone or in combination with other events or procedures (coronary artery bypass grafting or angioplasty). Suman L. Sood et al. Blood Adv 2018;2:1325-1333 © 2018 by The American Society of Hematology